Kyverna Therapeutics, Inc. (KYTX) Stock Price & Analysis
Kyverna Therapeutics, Inc. (KYTX) closed at USD 5.73 on Thursday, October 22, 2026, down 1.88% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 5.84; the Oct 22, 2026 session ranged USD 5.67–5.98 on volume of 518,877 shares. Market capitalization is $354.36M, with a 52-week range of USD 5.61–13.67 (NMS). Source: Nexqual, retrieved October 23, 2026 at 10:11 UTC.
Also available as compact Markdown for AI agents: nexqual.com/KYTX.md
Key facts (KYTX)
- Analysts: Buy (mean 1.67 on a 1–5 scale) (6 analysts), mean target USD 30.4 (range 25–33).
- Total return with dividends: 1Y -10.5% vs S&P 500 +14.9%; 5Y -81.0% vs S&P 500 +80.3%.
- Next earnings: 2026-11-11, EPS estimate USD -0.69, revenue estimate $0K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (KYTX)
| USD | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|
| Operating income | -$62.4M | -$143M | -$170M | -$159M |
| Net income | -$60.4M | -$127M | -$161M | -$153M |
| EPS (diluted) | -$89.61 | -$3.33 | -$3.64 | — |
| Free cash flow | -$53.0M | -$116M | -$154M | — |
| Cash + short-term investments | $57.5M | $286M | $279M | — |
| Total debt | — | — | $24.7M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (KYTX)
P/B 2.1x · Earnings yield -43.07% · Net cash $175M · EV $180M
Analysts (KYTX)
Consensus Buy (mean 1.67 on a 1–5 scale), 6 analysts; mean target USD 30.4 (low 25, high 33).
Total return (dividends reinvested) (KYTX)
| 1Y (from 2025-10-23) | 5Y (from 2024-02-05) | |
|---|---|---|
| Total return | -10.5% | -81.0% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -10.5% | -45.8% |
| Volatility (annualized) | 91.4% | 85.0% |
| Max drawdown | -49.6% (Apr 2026→Oct 2026) | -93.8% (Feb 2024→Apr 2025) |
KYTX suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Intellia Therapeutics, Inc. (NTLA) | “To that end, we established a partnership with Intellia to create allogeneic T-cell therapies.” |
| Partner | GILEAD SCIENCES, INC. (GILD) | “In January 2020, the Company entered into the Collaboration, Option and License Agreement (the "Gilead Agreement") with Gilead Sciences, Inc. ("Gilead").” |
| Partner | Minaris Advanced Therapies | “Under the master services agreement with MAT, MAT's facility in Philadelphia, Pennsylvania, provides us with certain customized cell manufacturing, release and testing services for our miv-cel product candidate.” |
| Partner | Oxford Finance | “Covenants and other provisions in the Loan and Security Agreement with Oxford Finance may restrict our business and operations, and if we do not effectively manage our covenants, our financial conditions and results of operations could be adversely affected.” |
| Partner | ElevateBio BaseCamp | “Under our Development and Manufacturing Services Agreement with Elevate, dated July 2023, or the Elevate Agreement, we engaged Elevate in November 2024 to provide us with cell manufacturing, release and testing services for our miv-cel product candidate.” |
| Partner | Westlake BioPartners Fund I | “*Plan provides for the distribution in-kind of shares of our common stock to partners or members of Westlake BioPartners Fund I, L.P. and Westlake BioPartners GP I, LLC and does not cover any sales of shares of our common stock.” |
| Partner | Westlake BioPartners GP I | “*Plan provides for the distribution in-kind of shares of our common stock to partners or members of Westlake BioPartners Fund I, L.P. and Westlake BioPartners GP I, LLC and does not cover any sales of shares of our common stock.” |
| Partner | The Nasdaq Stock Market | “Under the rules and listing standards of The Nasdaq Stock Market LLC, or the Nasdaq Rules, a majority of the members of our board of directors must satisfy the Nasdaq criteria for "independence." No director qualifies as independent under the Nasdaq Rules unless our board of directors affirmatively determines that the director does not have a relationship with us that would impair independence (directly or as a pa…” |
Quoted from the company's 10-K filed Mar 26, 2026.
Companies that name KYTX in their SEC reports
| Relationship to KYTX | Company | Filing | Sentence |
|---|---|---|---|
| partner | Intellia Therapeutics, Inc. (NTLA) | 10-K Feb 26, 2026 | “In December 2021, we entered into a licensing and collaboration agreement with Kyverna Therapeutics, Inc. ("Kyverna"), a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases, for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases.” |
KYTX company outlook (results filed Aug 11, 2026)
- “KYSA-8 12-month topline data expected in Q3 2026 Enrollment in KYSA-6 Phase 3 trial in generalized myasthenia gravis (gMG) expected to be completed in mid-2027; longer-term follow-up Phase 2 topline data expected in Q3 2026 Reiterates operating runway into 2028 EMERYVILLE, Calif., August 11, 2026 -- Kyverna Therapeutics, Inc.”
Quoted word-for-word from the SEC 8-K results press release.
KYTX analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.69 | $-0.74 | -6.4% | $0 | 5 |
| Next quarter (ends Dec 2026) | $-0.80 | $-0.81 | -1.6% | $0 | 5 |
| Current fiscal year (ends Dec 2026) | $-2.77 | $-2.88 | -3.7% | $0 | 5 |
| Next fiscal year (ends Dec 2027) | $-3.17 | $-2.95 | +7.3% | $17.2M | 5 |
Key Statistics (as of October 23, 2026 at 10:11 UTC)
| Price | USD 5.73 |
|---|---|
| Change | ▼ 1.88% (down) |
| Previous Close | USD 5.84 |
| Open | USD 5.83 |
| Day Range | USD 5.67 – 5.98 |
| 52-Week Range | USD 5.61 – 13.67 |
| Volume | 518,877 shares |
| Market Cap | $354.36M |
| Exchange | NMS |
Technical Analysis (KYTX)
Nexqual's technical model rates KYTX "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 10:11 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 32.84 (neutral) |
| vs SMA50 | Below (USD 7.25) |
| MACD | -0.4 (negative) |
Analyst Ratings (KYTX)
Wall Street analysts rate KYTX "Buy" based on 6 analysts, with a mean price target of USD 30.4 (range USD 25–33), per Nexqual as of October 23, 2026 at 10:11 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 30.4 |
| High Target | USD 33 |
| Low Target | USD 25 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (KYTX)
| Next Earnings Date | 2026-11-11 |
|---|---|
| EPS Estimate | USD -0.69 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.63 vs est -0.68 ▲ beat |
| 2025-12-31 | USD -0.8 vs est -0.86 ▲ beat |
| 2025-09-30 | USD -0.85 vs est -0.95 ▲ beat |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Financials & Fundamentals (KYTX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -87.24% |
| Debt / Equity | 0.2 |
| Current Ratio | 9.06 |
| Total Cash | $199.43M |
| Total Debt | $33.00M |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Financial Health Score (KYTX)
Nexqual rates Kyverna Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:11 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $199M cash and investments vs $25M debt (Jun 2026, SEC), net cash |
| Cash Flow | Weak — Operating cash flow -$154M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -87%, ROA -44.5% |
Ownership (KYTX)
| Insider Ownership | +6.98% |
|---|---|
| Institutional Ownership | +81.29% |
| Shares Outstanding | 61.84M |
| Float | 36.07M |
| Short % of Float | +18.26% |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
Leadership (KYTX)
Kyverna Therapeutics, Inc. is led by Warner Biddle, CEO & Director, per Nexqual as of October 23, 2026 at 10:11 UTC.
| CEO & Director | Warner Biddle |
|---|---|
| Chief Financial Officer | Gregory Martini |
| Chief Technology Officer | Mayo Pujols |
| Senior Vice President of Corporate Affairs | Tracy Rossin |
Major Backers & Investors (KYTX)
Notable institutional backers of Kyverna Therapeutics, Inc. include GordonMD Global Investments LP, Gilead Sciences Inc, Bain Capital Life Sciences Investors, LLC, according to Nexqual as of October 23, 2026 at 10:11 UTC.
Active Investors
| Investor | Stake |
|---|---|
| GordonMD Global Investments LP | 6.86% |
| Gilead Sciences Inc | 6.67% |
| Bain Capital Life Sciences Investors, LLC | 4.67% |
| AIGH Capital Management LLC | 4.52% |
| Deerfield Management Company, L.P | 3.23% |
| Price (T.Rowe) Associates Inc | 1.92% |
| Insight Holdings Group, LLC | 1.6% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 5.07% |
| Vanguard Group | 3.07% |
| Geode Capital | 1.7% |
Source: Nexqual, October 23, 2026 at 10:11 UTC.
From Kyverna Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- In January 2026, the Investigational New Drug, or IND, application for KYV-102, our proprietary whole blood, rapid manufacturing process, was accepted by the U.S.
- We have developed a robust manufacturing process for miv-cel and partnered with ElevateBio BaseCamp, Inc., or Elevate, and Minaris Advanced Therapies Inc, or MAT, two experienced contract development and manufacturing organizations, to generate miv-cel for our Kyverna-sponsored clinical trials, investigator-initiated trials and named patient activities.
Partnerships
- To that end, we established a partnership with Intellia to create allogeneic T-cell therapies.
Legal & Regulatory Risks (Item 1A, quoted)
- We have conducted, are currently conducting, and may in the future conduct clinical trials for our product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials.
- We have conducted, are currently conducting, and may in the future conduct one or more clinical trials of our current or future product candidates outside of the United States.
- Any delay or failure in obtaining required approvals could adversely affect our ability to generate revenue from the particular product candidate for which we are seeking approval. Furthermore, any regulatory approval to market a product may be subject to limitations on the approved uses for which we may market the product or on the labeling or other restrictions.
- We are also subject to or may in the future become subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 90.9 | ▲ 2.57% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| ABVX | Abivax SA | USD 90.23 | ▼ 3.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:11 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt